<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02635750</url>
  </required_header>
  <id_info>
    <org_study_id>1289.24</org_study_id>
    <secondary_id>2015-001694-40</secondary_id>
    <nct_id>NCT02635750</nct_id>
  </id_info>
  <brief_title>Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female Subjects</brief_title>
  <official_title>A Study to Investigate the Pharmacokinetic Drug-drug Interaction Following Oral Administration of BI 409306 and Donepezil in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Part I:&#xD;
&#xD;
      To investigate whether and to what extent donepezil affects single dose pharmacokinetics of&#xD;
      BI 409306&#xD;
&#xD;
      Part II:&#xD;
&#xD;
      To investigate whether and to what extent BI 409306 affects the single dose pharmacokinetics&#xD;
      of donepezil&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In Part 1: AUC0-tz</measure>
    <time_frame>up to 16 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In Part 1: Cmax</measure>
    <time_frame>up to 16 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In part 2: AUC0-tz</measure>
    <time_frame>up to 168.5 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In part 2: Cmax</measure>
    <time_frame>up to 168.5 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In Part 1: AUC 0-infinity</measure>
    <time_frame>up to 16 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Part 2: AUC0-infinity</measure>
    <time_frame>up to 168.5 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 409306</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Donepezil low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Donepezil high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <arm_group_label>BI 409306</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil low dose</intervention_name>
    <arm_group_label>Donepezil low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil high dose</intervention_name>
    <arm_group_label>Donepezil high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Healthy male/female subjects,&#xD;
&#xD;
          -  age of 18 to 55 years,&#xD;
&#xD;
          -  body mass index (BMI) of 18.5 to 29.9 kg/m2&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the study in&#xD;
             accordance with GCP and local legislation&#xD;
&#xD;
          -  Male subjects, or female subjects who meet any of the following criteria starting from&#xD;
             at least 30 days before the first administration of trial medication and until 30 days&#xD;
             after trial completion:&#xD;
&#xD;
          -  Use of adequate contraception, e.g. any of the following methods plus condom:&#xD;
&#xD;
        intrauterine device (non-hormonal)&#xD;
&#xD;
          -  Sexually abstinent&#xD;
&#xD;
          -  A vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)&#xD;
&#xD;
          -  Surgically sterilised (including hysterectomy)&#xD;
&#xD;
          -  Postmenopausal, defined as at least 1 year of spontaneous amenorrhea (in questionable&#xD;
             cases a blood sample with simultaneous levels of FSH above 40 U/L and estradiol below&#xD;
             30 ng/L is confirmatory)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Any finding in the medical examination (including BP, PR or ECG) is deviating from&#xD;
             normal and judged as clinically relevant by the investigator&#xD;
&#xD;
          -  Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg,&#xD;
             diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the&#xD;
             range of 60 to 90 bpm&#xD;
&#xD;
          -  Any laboratory value outside the reference range that the investigator considers to be&#xD;
             of clinical relevance&#xD;
&#xD;
          -  Any evidence of a concomitant disease judged as clinically relevant by the&#xD;
             investigator&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          -  Surgery of the gastrointestinal tract that could interfere with kinetics of the trial&#xD;
             medication (except appendectomy and simple hernia repair)&#xD;
&#xD;
          -  Diseases of the central nervous system (including but not limited to any kind of&#xD;
             seizures or stroke), and other relevant neurological or psychiatric disorders&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells, or blackouts&#xD;
&#xD;
          -  Chronic or relevant acute infections&#xD;
&#xD;
          -  History of relevant allergy or hypersensitivity (including allergy to the trial&#xD;
             medication or its excipients)&#xD;
&#xD;
          -  Intake of drugs with a long half-life (more than 24 h) within 30 days or less than 10&#xD;
             half-lives of the respective drug prior to administration of trial medication&#xD;
&#xD;
          -  Within 10 days prior to administration of trial medication, use of drugs that might&#xD;
             reasonably influence the results of the trial or that might prolong the QT/QTc&#xD;
             interval&#xD;
&#xD;
          -  Participation in another trial where an investigational drug has been administered&#xD;
             within 60 days prior to planned administration of trial medication&#xD;
&#xD;
          -  Smoker&#xD;
&#xD;
          -  Alcohol abuse Further exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>December 17, 2015</study_first_submitted>
  <study_first_submitted_qc>December 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2015</study_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
    <mesh_term>BI 409306</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

